TITLE

HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications

AUTHOR(S)
ANDREONI, M.; GIACOMETTI, A.; MAIDA, I.; MERAVIGLIA, P.; RIPAMONTI, D.; SARMATI, L.
PUB. DATE
November 2012
SOURCE
European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 11, p1473
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Hepatitis C virus (HCV) is the cause of more than three-quarters of liver-related deaths in HIV-seropositive individuals and it is remarkable that today approximately one-quarter of HIV-infected individuals in Europe and the USA have a HCV coinfection. HIV/HCV coinfected patients were more likely to develop cirrhosis, had an increased risk of developing AIDS, of HIV-related disease and of overall mortality. How HCV may affect the course of HIV infection is not well known even if it was suggested that HCV co-infection is able to increase immune activation and to sensitize CD4+ T-cells towards apoptosis in the absence of HIV therapy. There are many evidences that the simultaneous presence of HIV infection accelerates the liver damage from HCV favouring the evolution to cirrhosis in co-infected patients. HIV increasing of TNF alpha liver production and of HCV replication in peripheral blood lymphomonocytes are the mechanisms at the basis of this phenomenon. HAART had a positive effect on HIV/HCV co-infection, otherwise it does not appear to fully correct the adverse effect of HIV infection on HCV-related outcomes. Traditional treatment with pegilated Interferon plus ribavirin have low rates of sustained virological response in co-infected patients especially if infected with HCV genotype 1, and better results were often obtained in patients in which the use of antiretroviral treatment was avoided to reduce the occurrence of adverse effects. The recent preliminary results on the use of anti-HCV protease inhibitor drugs, boceprevir and telapravir, in co-infected people seems to demonstrate an enhanced antiviral efficacy in the HIV/HCV co-infected population of triple anti-HCV treatment even is some important limitation as interactions with antiretroviral agents and selection of HCV drug resistance, lead to consider the need for further studies designed to assess the best therapeutic strategies.
ACCESSION #
83079974

 

Related Articles

  • Abnormal Cytokine Production by Circulating Monocytes and Dendritic Cells of Myeloid Origin in ART-Treated HIV-1+ Patients Relates to CD4+ T-Cell Recovery and HCV Co-Infection. Almeida, Maria; Cordero, Miguel; Almeida, Julia; Orfao, Alberto // Current HIV Research;Jul2007, Vol. 5 Issue 3, p325 

    HIV-1 infection is associated with dysregulation of cytokine production by peripheral blood (PB) monocytes and dendritic cells (DC), but controversial results have been reported. We aimed to analyze the effect of antiretroviral therapy (ART) on the in vitro production of inflammatory cytokines...

  • Therapeutic Interventions for HIV Infection and Chronic Viral Hepatitis. Cooper, Curtis L. // Clinical Infectious Diseases;7/1/2005 Supplement, Vol. 41, pS69 

    Combination antiretroviral therapy reduces overall and liver-specific morbidity and mortality in coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) and represents the most beneficial pharmaceutical treatment intervention for most coinfected patients. Antiviral...

  • Impact of Chronic Hepatitis B Virus (HBV) Infection on Outcomes of Patients Infected with HIV in an Area Where HBV Infection Is Hyperendemic. Sheng, Wang-Huei; Chen, Mao-Yuan; Hsieh, Szu-Min; Hsiao, Chin-Fu; Wang, Jann-Tay; Hung, Chien-Ching; Chang, Shan-Chwen // Clinical Infectious Diseases;5/15/2004, Vol. 38 Issue 10, p1471 

    Between June 1994 and February 2003, a total of 111 human immunodeficiency virus (HIV)-infected patients with chronic hepatitis B virus (HBV) coinfection and 387 HIV-infected patients without HBV or hepatitis C virus coinfection were prospectively observed to assess the impact of HBV infection...

  • Hepatitis C Virus Is Infrequently Evaluated and Treated in an Urban HIV Clinic Population. Scott, John D.; Wald, Anna; Kitahata, Mari; Krantz, Elizabeth; Drolette, Linda; Corey, Lawrence; Wang, Chia C. // AIDS Patient Care & STDs;Nov2009, Vol. 23 Issue 11, p925 

    This retrospective cohort study of HIV/hepatitis C virus (HCV) coinfected patients evaluated time trends and rates of HCV evaluation for patients seen between January 1, 1997 and October 30, 2004. Survival analysis and Cox proportional hazards modeling were used to describe the time to...

  • Virological response reduces mortality in HIV/hepatitis C coinfection. Levitan, Dave // Infectious Disease News;Apr2008, Vol. 21 Issue 4, p28 

    The article discusses research on the association between sustained virological response (SVR) to interferon plus ribavirin and reduction in liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus. It references a study by J. Berenguer et al, presented at...

  • ANTI-AIDS VIRUS. Stoppani, Jim // Joe Weider's Muscle & Fitness;Jun2004, Vol. 65 Issue 6, p234 

    Discusses research being done on anti-AIDS virus as of June 2004. Purpose of inactivated viruses to patients; Observations made by scientists from the National Institute of Allergy and Infectious Diseases on the effect of GB virus C on HIV-infected patients; Assumption on a previously-released...

  • Does HCV make HIV infection worse? Mascolini, Mark // Research Initiative/Treatment Action!;Summer2014, Vol. 19 Issue 1, p20 

    The article discusses impact of hepatitis C virus (HCV) infection on HIV infection. Topics discussed include impact of HCV infection on mortality of HIV people, on response to combination antiretroviral therapy (cART), and on clinical outcomes and progression to AIDS. Two U.S. studies on HCV/HIV...

  • Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-a and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients. de Castellarnau, Montserrat; Aparicio, Ester; Parera, Mariona; Franco, Sandra; Tural, Cristina; Clotet, Bonaventura; Mart´┐Żnez, Miguel Angel // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Previous works have documented the contribution of different IL28B-associated SNPs to spontaneous HCV clearance. This study investigated the effect of different interleukin (IL) 28B genetic variants on interferon (IFN)-based therapy response. We genotyped eight IL28B single-nucleotide...

  • Acute HCV in HIV-Positive Individuals -- A Review. Danta, M.; Dusheiko, G. M. // Current Pharmaceutical Design;Jun2008, Vol. 14 Issue 17, p1690 

    HCV/HIV co-infection is a major public health problem with between 10-25% of HIV-positive individuals infected with HCV. Following the introduction of effective HIV therapies, HCV has become a leading cause of morbidity and mortality in the HIV population. Since the early 2000s, there has been a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics